Tag

Your search for Difficult-to-treat patients returned 20 results.


Exclusive HCV Interview: Julio Gutierrez, MD

So my first question is what do you see as the biggest challenges associated with the hepatitis C epidemic in the U.S.? JULIO GUTIERREZ: There are three main challenges currently associated with eradicating hepatitis C in the United States: Most patients in the US are still not receiving care for their hepatitis C infection. In order to cure HCV in these ...

Read More


Exclusive Hepatitis C Interview: Daryl Luster

So my first question is, can you please tell me a little bit about yourself? DARYL LUSTER: Oh, gosh, what’s to tell? I’m 61 this month. Regarding my background, if somebody had said to me 10, even 15 years ago, that I would be involved in health advocacy, I would have said, huh?  No. Really? So it’s been a real shift for me. I come from a business ...

Read More


Key AASLD 2015 HCV Abstracts: Dr. Lebovics

For more information on the selected AASLD 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Decreased work productivity in patients with chronic hepatitis C Abstract 18 Reduced Work Productivity (WP), Absenteeism and Presenteeism of Patients Infected with ...

Read More


C-SALVAGE: Final 24-week Follow-up Results

Non-cross-resistant drugs are needed for salvage therapy of patients with chronic hepatitis C virus infection who do not achieve sustained virologic response on direct acting antiviral (DAA) regimens. The final follow-up week 24 results from the C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy), have been published in the journal ...

Read More


Tx Options for HCV GT 1 or 4 Non-responders

New study shows that genotype 1- or 4-infected non-responders, including patients with cirrhosis, achieve high SVR12 rates on the 24 week, quad treatment regimen of daclatasvir plus asunaprevir and peginterferon/ribavirin. The combination was well tolerated and no additional safety and tolerability concerns were observed compared with peginterferon/ribavirin regime...

Read More


Two DAA regimen in cirrhotic HCV GT1b patients

New Phase 2 clinical trial results indicate that an all-oral interferon- and ribavirin-free regimen of ombitasvir, paritaprevir, and ritonavir is generally well tolerated and associated with high rates of SVR12 in both cirrhotic and noncirrhotic patients with HCV genotype 1b infection who were treatment-naive or treatment experienced, including prior null responders, ...

Read More


Real-world impact of sofosbuvir HCV regimens

New study addresses the real-world effectiveness of sofosbuvir (SOF)-based anti-HCV regimens in a diverse patient population consisting of difficult to treat patients. More than a quarter of the assessed US Veterans Affairs (VA) population with chronic HCV infection were African American, almost 90% were over the age of 55, over a third were overweight, and substan...

Read More


Addressing the Restricted Use of DAA therapies

Results of a new US cost effectiveness study indicate that effective direct acting antiviral (DAA) therapies should be not be restricted to only those HCV-infected patients with advanced fibrosis. Authors note that as a society, we have an opportunity to eliminate hepatitis C by taking appropriate and timely steps, and we should be willing to pay for the current HCV ...

Read More


HCV DAAs and Severe Renal Impairment

New report provides vital information needed by clinicians to treat HCV in patients with severe renal impairment with the approved DAAs simeprevir and sofosbuvir. Available clinical information on the use of sofosbuvir in patients with severe renal impairment is minimal, and there are currently no approved direct acting antiviral (DAA) treatments in this popula...

Read More


Liver transplant failure risk: Females with HCV

Prospective Liver Match study unequivocally shows that female gender is a risk factor for graft loss after liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Women lose their graft more frequently than men, secondary to more aggressive recurrent HCV infection. This study also confirms that the use of elderly donors is a strong predictor of poor ...

Read More